Courtney Flaherty

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

Laurence Albigès, MD, PhD, discusses what inspired the launch of the CaboPoint study examining second-line cabozantinib in patients with advanced renal cell carcinoma, the efficacy of this approach, and the next steps for this research.

Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.

Boris A. Hadaschik, MD, discusses results from a post-hoc analysis of subsequent therapy for patients with nonmetastatic castration-resistant prostate cancer who progressed following treatment with apalutamide.

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.

Al-Ola A. Abdallah, MD, discusses updated safety and efficacy data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population.

An increasing focus on antibody-drug conjugates for HER2-positive breast cancer signals a potential shift in the standard of care for this population.

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

Mariana Chavez-MacGregor, MD, MSC, discussed key efficacy and safety data from the SWOG 1207 trial of adjuvant everolimus in postmenopausal patients with high-risk, hormone receptor–positive breast cancer.

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

Matthew Brunner, MD, discusses how key patient factors, the use of advanced imaging modalities, and the relationship between community and academic centers influence treatment approaches in relapsed/refractory multiple myeloma.

Scott Kopetz, MD, discussed the key objectives of the phase 3 BREAKWATER trial being done in patients with BRAF V600E–mutated mCRC, the recently reported safety and efficacy data observed with encorafenib plus cetuximab and chemotherapy, and the importance of conducting biomarker research to further personalize treatment in these patients.

Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .

Rachna T. Shroff, MD, MS, expands on the rationale for evaluating the addition of nab-paclitaxel to gemcitabine/cisplatin in patients with newly diagnosed biliary tract cancers, data presented from SWOG 1815, and how this study may pave the way for future research efforts in the paradigm.

Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.

Ryan Jacobs, MD, highlighted the updated safety and efficacy results from the minimal residual disease cohort of the CAPTIVATE trial, discussed unanswered questions regarding minimal residual disease as a predictive vs prognostic tool in patients with chronic lymphocytic leukemia, and outlined areas that are ripe for further exploration.

Nicholas P. McAndrew, MD, MSCE, discusses the need for HER2-targeted TKIs specifically designed to penetrate the blood-brain barrier, updated clinical data on the safety and tolerability of DZD1516 monotherapy, and the implications of nonclinical data on DZD1516 for treating CNS metastases in HER2-positive breast cancer.

Martin Dreyling, MD, discusses the safety and efficacy data from the TRIANGLE study done in patients with previously untreated MCL who are younger than 66 years, and the impact of these results on the use of ASCT in this population.

Ana Baramidze, MD, provides background on the FDA approvals of cemiplimab in NSCLC, expands on key efficacy and safety data with cemiplimab from EMPOWER-Lung 3, and discusses the current treatment landscape for patients with advanced NSCLC.

Carsten Niemann, MD, PhD, discusses the significance of new data from the GLOW trial, the potential relationship between treatment regimen, minimal residual disease status, and survival outcomes, and the importance of research into precision medicine approaches in chronic lymphocytic leukemia.

Tanios S. Bekaii-Saab, MD, FACP, expands on key data reported from the MOUNTAINEER trial, the potential effects of this regimen’s approval on the current treatment landscape, and the continued investigation of this and other targeted approaches in metastatic colorectal cancer.

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.

Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

Chan Y. Cheah, MD, MBBS, discusses the the phase 1 BGB-11417-101 trial, which showed that the BCL-2 inhibitor BGB-11417, administered alone or in combination with the BTK inhibitor zanubrutinib, induced promising response rates and was well tolerated patients with chronic lymphocytic leukemia.

Maryam Lustberg, MD, MPH, discusses key results from a retrospective analysis of ovarian suppression in HR–positive, HER2-positive breast cancer, the importance of assessing real-world practice patterns, and the need for continued study of other predictive biomarkers for endocrine therapy in this population.